Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW, Tsai XC, Hou HA, Tien FM, Liu JH, Chou WC, Ko BS, Chen YW, Lin CC, Cheng CL, Lo MY, Lin YC, Lu LC, Wu SJ, Kuo SH, Hong RL, Huang TC, Yao M. Wang YW, et al. Among authors: lo my. Ann Hematol. 2022 Feb;101(2):349-358. doi: 10.1007/s00277-021-04711-9. Epub 2021 Nov 11. Ann Hematol. 2022. PMID: 34766217 Clinical Trial.
Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Ni SC, Yao M, Tseng MH, Kuo YY, Liu MC, Tang JL, Sun HI, Chuang YK, Chou WC, Hou HA, Tien HF. Lee WH, et al. Among authors: lo my. Am J Hematol. 2023 Mar;98(3):398-407. doi: 10.1002/ajh.26799. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588411 Free article.
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY, Tsai XC, Lin CC, Tien FM, Kuo YY, Lee WH, Peng YL, Liu MC, Tseng MH, Hsu CA, Chen JC, Lin LI, Sun HI, Chuang YK, Ko BS, Tang JL, Yao M, Chou WC, Hou HA, Tien HF. Lo MY, et al. Am J Hematol. 2023 May;98(5):760-769. doi: 10.1002/ajh.26892. Epub 2023 Mar 13. Am J Hematol. 2023. PMID: 36861732 Free article.
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH, Tsai MT, Tsai CH, Tien FM, Lo MY, Tseng MH, Kuo YY, Liu MC, Yang YT, Chen JC, Tang JL, Sun HI, Chuang YK, Lin LI, Chou WC, Lin CC, Hou HA, Tien HF. Lee WH, et al. Among authors: lo my. Blood Cancer J. 2023 Aug 9;13(1):120. doi: 10.1038/s41408-023-00894-8. Blood Cancer J. 2023. PMID: 37558665 Free PMC article.
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.
Tien FM, Yao CY, Tsai XC, Lo MY, Chen CY, Lee WH, Lin CC, Kuo YY, Peng YL, Tseng MH, Wu YS, Liu MC, Lin LI, Chuang MK, Ko BS, Yao M, Tang JL, Chou WC, Hou HA, Tien HF. Tien FM, et al. Among authors: lo my. Blood Cancer J. 2024 Jan 23;14(1):15. doi: 10.1038/s41408-023-00975-8. Blood Cancer J. 2024. PMID: 38253683 Free PMC article.
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Tseng MH, Kuo YY, Yu SC, Liu MC, Yuan CT, Yang YT, Chuang MK, Ko BS, Tang JL, Sun HI, Chuang YK, Tien HF, Hou HA, Chou WC. Lee WH, et al. Among authors: lo my. Blood Cancer J. 2024 Apr 9;14(1):57. doi: 10.1038/s41408-024-01031-9. Blood Cancer J. 2024. PMID: 38594285 Free PMC article.
47 results